HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma.

Autor:	Toh YL; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore., Pang YY; Division of Chemistry and Biological Chemistry, Nanyang Technological University, Singapore., Shwe M; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.; Oncology Pharmacy, National Cancer Centre Singapore, Singapore., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Toh CK; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Chan A; Oncology Pharmacy, National Cancer Centre Singapore, Singapore.; Department of Clinical Pharmacy Practice, University of California, Irvine, USA., Ho HK; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2020 Apr 27; Vol. 6 (4), pp. e03813. Date of Electronic Publication: 2020 Apr 27 (Print Publication: 2020).
DOI:	10.1016/j.heliyon.2020.e03813
Abstrakt:	Background: The selective occurrence of hepatotoxicity observed with use of pazopanib may be attributed to its high level of plasma protein binding and low hepatic extraction ratio. The primary objective was to investigate changes in free drug concentration amongst patients with varying albumin concentrations. Methods: A HPLC-MS/MS method using C18 column (4.6 × 150 mm, 5 μm) with ESI source in positive mode had been developed and validated for the quantitative determination of free pazaopanib concentration in human plasma. Prior to sample preparation, patient samples were subjected to 6-hour equilibrium dialysis with molecular weight cut-off set at 8000 Da. Results: The calibration curves were linear over the range of 5-1000 ng/mL, with a lower limit of quantification of 5 ng/mL. The intra-day and inter-day precisions and accuracies were all within ± 15 %, at 3 different quality controls. Higher median fraction unbound of pazopanib were observed in patients (n = 17) with lower than normal albumin concentrations. Conclusion: With the developed assay, monitoring of plasma free concentrations may be evaluated as an indicator of pazopanib exposure in patients. (© 2020 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu